Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Valiant Bets Against Credit as Hansen Sees Risks Markets Are Missing Stephen Taub Top Hedge Funds Are Reshaping Their Portfolios Stephen Taub Revitalizing US Infrastructure: Why Pension Capital Is the Missing Link Sponsored by IFM Investors